找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Approaching China‘s Pharmaceutical Market; A Fundamental Guide Ming Q. Lu Book 2015 Springer International Publishing Switzerland 2015 CFD

[復制鏈接]
樓主: Diverticulum
11#
發(fā)表于 2025-3-23 10:32:06 | 只看該作者
Erfolgreiche Strategiearbeit im Mittelstand of the articles that are most relevant to overseas pharmaceutical companies, and the major regulations related to drug registration, quality management, and inspection. The corresponding guidances are listed and will be discussed in the corresponding independent chapters.
12#
發(fā)表于 2025-3-23 16:39:43 | 只看該作者
Erfolgreiche Strategien für E-Commerceese State Council in 2008. In this chapter, we’ll briefly introduce the basic knowledge of the Chinese IPR system, the key regulatory policies, and the differences between China and western countries. We hope this section for Pharmaceutical Patent Protection may help overseas and multinational pharm
13#
發(fā)表于 2025-3-23 18:34:51 | 只看該作者
Unternehmensführung & Controllingt ones for multinational pharmaceutical companies and pharmacy school students to understand. We hope this chapter may help the readers get a basic idea of China’s regulatory environment through the understanding of the CFDA structure and function and its differences from its counterparts in the wes
14#
發(fā)表于 2025-3-24 02:05:48 | 只看該作者
15#
發(fā)表于 2025-3-24 03:00:36 | 只看該作者
16#
發(fā)表于 2025-3-24 06:41:18 | 只看該作者
https://doi.org/10.1007/978-3-8350-9511-3ous clinical phases have to follow the CFDA’s defined requirements; the investigator’s responsibilities and safety reporting requirements are very unique from those of the western world; all the clinical sites and investigators have to be certified by the CFDA to conduct the clinical trials; all eth
17#
發(fā)表于 2025-3-24 11:51:23 | 只看該作者
Ergebnisse der empirischen Untersuchung,ug registration in China, IMCT data shall be in line with the requirements of the CFDA regulations. In this section, we’ll introduce the development strategies with a focus on IMCT, its subtypes, the corresponding advantages and disadvantages of each potential pathway, the application processes, the
18#
發(fā)表于 2025-3-24 16:28:25 | 只看該作者
19#
發(fā)表于 2025-3-24 20:15:26 | 只看該作者
20#
發(fā)表于 2025-3-25 02:29:51 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2025-10-13 02:52
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
南阳市| 成都市| 镇坪县| 高要市| 湟源县| 河南省| 宁陵县| 桦南县| 古蔺县| 东海县| 佳木斯市| 阜宁县| 湖口县| 崇明县| 巢湖市| 汤阴县| 黄浦区| 平乡县| 明溪县| 永安市| 潢川县| 德令哈市| 黄山市| 龙井市| 维西| 洪江市| 泰来县| 古交市| 崇左市| 永清县| 平度市| 东乡| 天台县| 扎鲁特旗| 阿克陶县| 绥江县| 舟山市| 香港 | 北宁市| 海门市| 永川市|